<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390698</url>
  </required_header>
  <id_info>
    <org_study_id>OFA</org_study_id>
    <nct_id>NCT04390698</nct_id>
  </id_info>
  <brief_title>Opioid Free Anesthesia in Breast Cancer Surgery</brief_title>
  <official_title>Opioid Free Anesthesia in Breast Cancer Surgery: a Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A comparison of incidences of postoperative nausea and vomiting (PONV) , postoperative pain
      severity and recovery parameters in breast cancer patients receiving opioid or opioid-free
      general anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer is one of the most common oncologic diagnosis in women. Surgery is
      traditionally performed under general anesthesia with opioid‑based analgesia. It is
      associated with higher incidences of PONV, more severe acute postoperative pain and increased
      incidences of chronic pain. The possibility of higher risk of metastasis has also been
      reported.

      The purpose of our study is to compare the opioid‑free general anesthesia with the
      opioid‑based general anesthesia with respect to the primary outcome measures of PONV and
      secondary outcome measures of pain relief, analgesic requirement , incidence of chronic pain,
      cancer recurrence and metastasis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative nausea and vomiting</measure>
    <time_frame>up to 24 hours after surgery</time_frame>
    <description>evaluated using a 0-10 scale, and 10 indicating the worst outcomes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>health related quality of life</measure>
    <time_frame>up to 3 months after surgery</time_frame>
    <description>evaluated using EQ-5D questionnare</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chronic pain</measure>
    <time_frame>up to 3 months after surgery</time_frame>
    <description>using 0-10 NRS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cancer recurrence and metastasis</measure>
    <time_frame>up to 12 months after surgery</time_frame>
    <description>diagnosed by breast cancer specialist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain severity</measure>
    <time_frame>up to 24 hours after surgery</time_frame>
    <description>using 0-10 NRS scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Opioid Free Anesthesia</condition>
  <arm_group>
    <arm_group_label>nerve block+opioid-free general anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paravertebral block with an ultrasound-guided technique; opioid-free general anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham bock+opioid general anesthesia</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham block by local infiltration at the same site of paravertebral block; opioid based general aneshesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>paravertebral block</intervention_name>
    <description>Paravertebral block will be performed at T2,T4 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.4% ropivacaine 20ml at each injection site.</description>
    <arm_group_label>nerve block+opioid-free general anesthesia</arm_group_label>
    <other_name>nerve block</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>opioid free anesthesia</intervention_name>
    <description>propofol, lidocine and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained with continuous infusion of propofol and dexmedetomidine.</description>
    <arm_group_label>nerve block+opioid-free general anesthesia</arm_group_label>
    <other_name>opioid free</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sham block</intervention_name>
    <description>Local infiltration at the same site of paravertebral block will be performed, with 1% lidocaine 3ml on each injection site.</description>
    <arm_group_label>sham bock+opioid general anesthesia</arm_group_label>
    <other_name>local infiltration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>opioid general anesthesia</intervention_name>
    <description>propofol, sufentanil and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained with continuous infusion of propofol and remifentanil.</description>
    <arm_group_label>sham bock+opioid general anesthesia</arm_group_label>
    <other_name>traditional general aneshesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        first diagnosis of histologically confirmed primary breast cancer; undergoing radical
        mastectomy; patients with I or II staging based on TNM staging system; ASA physical statue
        I-II;

        Exclusion Criteria:

        smoking history, chronic pain and opioid administration history; allergy to local
        anesthetics or NSAIDs; coagulation disorders; local infection at regional block site; a
        history of motion sickness, or a previous episode of PONV; unable to comply to study
        protocol schedule for logistic or other reasons; refusal to participate to the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Feng, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Feng, MD,PhD</last_name>
    <phone>86-010-88325581</phone>
    <email>littlevon@163.com</email>
  </overall_contact>
  <results_reference>
    <citation>Shirakami G, Teratani Y, Segawa H, Matsuura S, Shichino T, Fukuda K. Omission of fentanyl during sevoflurane anesthesia decreases the incidences of postoperative nausea and vomiting and accelerates postanesthesia recovery in major breast cancer surgery. J Anesth. 2006;20(3):188-95.</citation>
    <PMID>16897238</PMID>
  </results_reference>
  <results_reference>
    <citation>Tripathy S, Rath S, Agrawal S, Rao PB, Panda A, Mishra TS, Nayak S. Opioid-free anesthesia for breast cancer surgery: An observational study. J Anaesthesiol Clin Pharmacol. 2018 Jan-Mar;34(1):35-40. doi: 10.4103/joacp.JOACP_143_17.</citation>
    <PMID>29643620</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 8, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Yi Feng, MD</investigator_full_name>
    <investigator_title>Chief of the Anesthesiology Department</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

